These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Ko WK; Li Q; Bezard E Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591 [TBL] [Abstract][Full Text] [Related]
23. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628 [TBL] [Abstract][Full Text] [Related]
24. Slow wave activity across sleep-night could predict levodopa-induced dyskinesia. Amato N; Caverzasio S; Manconi M; Staedler C; Kaelin-Lang A; Galati S Sci Rep; 2023 Sep; 13(1):15468. PubMed ID: 37726375 [TBL] [Abstract][Full Text] [Related]
25. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β. Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895 [TBL] [Abstract][Full Text] [Related]
27. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients. Dias CMV; Leal DAB; Brys I Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453 [No Abstract] [Full Text] [Related]
28. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Calabresi P; Di Filippo M; Ghiglieri V; Tambasco N; Picconi B Lancet Neurol; 2010 Nov; 9(11):1106-17. PubMed ID: 20880751 [TBL] [Abstract][Full Text] [Related]
29. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Shin E; Rogers JT; Devoto P; Björklund A; Carta M Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357 [TBL] [Abstract][Full Text] [Related]
30. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842 [TBL] [Abstract][Full Text] [Related]
31. Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia. Prescott IA; Liu LD; Dostrovsky JO; Hodaie M; Lozano AM; Hutchison WD Neurobiol Dis; 2014 Nov; 71():24-33. PubMed ID: 25116960 [TBL] [Abstract][Full Text] [Related]
32. Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. Picconi B; De Leonibus E; Calabresi P J Neural Transm (Vienna); 2018 Aug; 125(8):1263-1271. PubMed ID: 29492662 [TBL] [Abstract][Full Text] [Related]
33. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease? Picconi B; Calabresi P Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264 [TBL] [Abstract][Full Text] [Related]
35. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101 [TBL] [Abstract][Full Text] [Related]
36. Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. Francardo V; Cenci MA Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S20-2. PubMed ID: 24262181 [TBL] [Abstract][Full Text] [Related]
37. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
38. Blink reflex in Parkinson's disease with levodopa-induced dyskinesia. Iriarte LM; Chacon J; Madrazo J; Chaparro P Funct Neurol; 1989; 4(3):257-61. PubMed ID: 2792861 [TBL] [Abstract][Full Text] [Related]
39. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978 [TBL] [Abstract][Full Text] [Related]
40. Emerging drugs for levodopa-induced dyskinesia. Al Dakheel A; Beaulieu-Boire I; Fox SH Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]